Cue Biopharma Future Growth
Future criteria checks 2/6
Cue Biopharma is forecast to grow earnings and revenue by 1.7% and 50.9% per annum respectively while EPS is expected to grow by 18.5% per annum.
Key information
1.7%
Earnings growth rate
18.5%
EPS growth rate
Biotechs earnings growth | 31.5% |
Revenue growth rate | 50.9% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 09 Apr 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 20 | -77 | N/A | -86 | 4 |
12/31/2025 | 16 | -68 | N/A | -60 | 5 |
12/31/2024 | 9 | -57 | N/A | -49 | 5 |
12/31/2023 | 5 | -51 | -40 | -40 | N/A |
9/30/2023 | 4 | -52 | -40 | -40 | N/A |
6/30/2023 | 2 | -52 | -39 | -39 | N/A |
3/31/2023 | 0 | -52 | -41 | -41 | N/A |
12/31/2022 | 1 | -53 | -42 | -42 | N/A |
9/30/2022 | 9 | -47 | -42 | -42 | N/A |
6/30/2022 | 12 | -49 | -42 | -42 | N/A |
3/31/2022 | 14 | -46 | -39 | -39 | N/A |
12/31/2021 | 15 | -44 | -40 | -39 | N/A |
9/30/2021 | 7 | -47 | -36 | -35 | N/A |
6/30/2021 | 5 | -44 | -38 | -36 | N/A |
3/31/2021 | 4 | -44 | -35 | -33 | N/A |
12/31/2020 | 3 | -45 | -33 | -32 | N/A |
9/30/2020 | 4 | -43 | -32 | -32 | N/A |
6/30/2020 | 4 | -40 | -34 | -33 | N/A |
3/31/2020 | 4 | -38 | -33 | -33 | N/A |
12/31/2019 | 3 | -37 | -31 | -31 | N/A |
9/30/2019 | 3 | -39 | -28 | -28 | N/A |
6/30/2019 | 2 | -45 | -26 | -25 | N/A |
3/31/2019 | 2 | -43 | -26 | -25 | N/A |
12/31/2018 | 1 | -39 | -28 | -26 | N/A |
9/30/2018 | 1 | -38 | -26 | -24 | N/A |
6/30/2018 | 0 | -30 | -23 | -22 | N/A |
3/31/2018 | N/A | -27 | -20 | -18 | N/A |
12/31/2017 | N/A | -23 | -13 | -12 | N/A |
9/30/2017 | N/A | -16 | N/A | -12 | N/A |
6/30/2017 | N/A | -13 | N/A | -10 | N/A |
3/31/2017 | N/A | -10 | N/A | -8 | N/A |
12/31/2016 | N/A | -8 | N/A | -6 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 1UC is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 1UC is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 1UC is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 1UC's revenue (50.9% per year) is forecast to grow faster than the German market (5.5% per year).
High Growth Revenue: 1UC's revenue (50.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 1UC's Return on Equity is forecast to be high in 3 years time